Octagon Capital invests in public and private healthcare companies globally. We strive to build long-term investments and partner with our portfolio companies to support innovation. Octagon manages capital on behalf of global institutions including university endowments, non-profit foundations, family offices, pension funds and established asset managers.

Private Portfolio

  • 4D Molecular Therapeutics

    4D Molecular Therapeutics

    4DMT (NASDAQ: FDMT) is a gene therapy company with a transformative discovery platform that enables its “disease first” approach to product discovery and development.

  • Affinia Therapeutics

    Affinia Therapeutics

    Affinia is an innovative gene therapy company focused on helping people affected by devastating rare and non-rare diseases.

  • Aktis Oncology

    Aktis Oncology

    Aktis is a US-based biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.

  • Arctic Vision

    Arctic Vision

    Arctic Vision is a China based clinical stage ophthalmology company focused on developing innovative therapies for pan-ocular disease.

  • ArriVent Biopharma

    ArriVent Biopharma

    ArriVent is a US-based biopharma company dedicated to accelerating the global development of innovative biopharmaceutical products.

  • Biocytogen

    Biocytogen

    Biocytogen is an international biotechnology company with expertise spanning the entire process of new drug research and development.

  • Bioheng Biotech Co. Ltd

    Bioheng Biotech Co. Ltd

    Bioheng is a China-based clinical-stage biotechnology company  dedicated on developing novel cellular immunotherapy for cancer.

  • Century Therapeutics

    Century Therapeutics

    Century (NASDAQ: IPSC) is a US based leading cell therapy company utilizing iPSC to develop cell products with the potential to overcome the limitations of early autologous and allogeneic cell therapies.

  • Cullgen Inc.

    Cullgen Inc.

    Cullgen is a China based biopharmaceutical company dedicated to the treatment of diseases lacking effective therapeutic approaches.

  • EpimAb Biotherapeutics

    EpimAb Biotherapeutics

    EpimAb is a China-based clinical stage biotech company specializing in bispecific antibody development.

  • Everest Medicines

    Everest Medicines

    Everest Medicines (SEHK: 1952.HK) is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies.

  • Forge Biologics

    Forge Biologics

    Forge is a US-based gene therapy company with a promising pipeline of disease-modifying AAV-based therapies to potentially help patients with rare genetic diseases.

  • Shanghai Hanyu Medical Technology Co., Ltd.

    Hanyu Medical

    Hanyu Medical is a China-based medical device company committed to the R&D and commercialization of innovative medical devices for structural cardiology.

  • Harbour BioMed

    Harbour BioMed

    Harbour BioMed (SEHK: 2142.HK) is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and immunological diseases.

  • HeMo Bioengineering

    HeMo Bioengineering

    HeMo is a China-based neurovascular interventional devices innovative platform enterprise.

  • Hummingbird Bioscience

    Hummingbird Bioscience

    Hummingbird is a Singapore-based clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes.

  • Immune-Onc Therapeutics

    Immune-Onc Therapeutics

    Immune-Onc is a US-based clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints.

  • ImmVira Group Company

    ImmVira Group Company

    ImmVira is a China based biotechnology platform dedicated to the development of more effective and safer therapies against cancer.

  • New Horizon

    New Horizon

    New Horizon Health (SEHK: 6606.HK) is a leader and a pioneer in home testing for a number of different types of cancers and is China’s first biotech company focusing on early cancer screening.

  • NiKang Therapeutics

    NiKang Therapeutics

    NiKang Therapeutics is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs.

  • Numab Therapeutics

    Numab Therapeutics

    Numab is a Switzerland-based biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation.

  • Omega Therapeutics

    Omega Therapeutics

    Omega is a US-based development-stage biotech company pioneering the field of epigenomic programming to precisely regulate and control the human genome to treat and cure disease.

  • Shanghai Shenqi Medical Technology Co.

    SQ Medical Technology Co

    SQ Medical is a China-based medical device enterprise focused on cardiovascular intervention, peripheral vascular intervention and structural heart disease.

  • Sonoma Biotherapeutics

    Sonoma Biotherapeutics

    Sonoma Biotherapeutics is leading the development of adoptive T-cell (Treg) therapies for autoimmune and degenerative diseases.

  • StrideBio, Inc

    StrideBio, Inc

    StrideBio is a US-based leading developer of novel engineered adeno-associated virus (AAV) based gene therapies.

  • Taysha Gene Therapies

    Taysha Gene Therapies

    Taysha Gene Therapies (NASDAQ: TSHA) is a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease.

  • Vedere Bio II

    Vedere Bio II

    Vedere is a US-based company developing next generation ocular gene therapies designed for vision restoration and preservation.

  • Vera Therapeutics

    Vera Therapeutics

    Vera Therapeutics (NASDAQ: VERA) is a US based clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases.

  • Zylox Medical Device Co.

    Zylox Medical Device Co.

    Zylox (SEHK: 2190.HK) is a China-based medical device company focused on interventional and implantable peripheral vascular devices.

IPO Cornerstone Portfolio*

  • Antengene Corporation Limited

    Antengene Co. Ltd

    Antengene (SEHK: 6996.HK) is a biotech company with synergistic first-in-class, only-in-class and best-in-class cancer therapies that unlock the full therapeutic potential of its drug candidates.

  • Everest Medicines

    Everest Medicines

    Everest Medicines (SEHK: 1952.HK) is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies.

  • Harbour BioMed

    Harbour BioMed

    Harbour BioMed (SEHK: 2142.HK) is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and immunological diseases.

  • InnoCare Pharma Limited

    InnoCare Pharma Limited

    InnoCare (SEHK: 9969.HK) is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases.

  • Jacobio Pharmaceuticals Group Co., Ltd

    Jacobio Pharmaceuticals

    Jacobio (SEHK: 1167.HK) is a clinical-stage pharmaceutical company in China focusing on in-house discovery and development of innovative oncology therapies.

  • Joinn Laboratories

    Joinn Laboratories

    Joinn (SEHK: 6127.HK) is a pioneer of commercial GLP laboratories in China and is one of the oldest non-clinical safety evaluation institutes providing preclinical and non-clinical services.

  • Keymed Biosciences Inc.

    Keymed Biosciences Inc.

    Keymed (SEHK: 2162.HK) is a China-based biotechnology company focused on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas.

  • New Horizon

    New Horizon

    New Horizon Health (SEHK: 6606.HK) is a leader and a pioneer in home testing for a number of different types of cancers and is China’s first biotech company focusing on early cancer screening.

  • OcuMension Therapeutics

    OcuMension Therapeutics

    Ocumension Therapeutics (SEHK: 1477.HK) is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies.

  • Peijia Medical Limited

    Peijia Medical Limited

    Peijia Medical Limited (SEHK: 9996.HK) aims to become a world-renowned medical device platform that provides total treatment solutions for structural heart and neurovascular diseases.

  • RemeGen Co. Ltd

    RemeGen Co. Ltd

    RemeGen (SEHK: 9995.HK) is a biopharmaceutical company focused on the treatment of autoimmune, oncology and ophthalmic diseases with unmet needs in China and globally.

  • Zylox Medical Device Co.

    Zylox Medical Device Co.

    Zylox (SEHK: 2190.HK) is a China-based medical device company focused on interventional and implantable peripheral vascular devices.

Founder

Ting Jia (TJ)

Dr. Ting Jia, Ph.D., also known as TJ, is the Founder of Octagon Capital and has served as the firm’s Chief Investment Officer since 2019. Prior to founding Octagon Capital, TJ served as Managing Director at Hillhouse Capital Management. Before this, TJ was an investment analyst at BVF Partners and a management consultant at McKinsey’s New York office. TJ started his career as a research fellow at Memorial Sloan-Kettering Cancer Center. He received his Ph.D. in Immunology from Cornell University Weill Medical College and a B.S. with first honor in Biological Sciences from Sun Yat-sen University.

Careers

We are always looking for exceptional and talented people to join the team at Octagon Capital. We believe the opportunity to work alongside our team members that share core values in intellectual curiosity, humility and integrity would be both challenging and rewarding. If you are interested in joining the Octagon Capital team, please submit your resume at careers@octagoninvest.com

 

Contact Us

+1-212-369-2829

654 Madison Ave, 16th Floor
New York, NY 10065